TimesSquare Capital Management LLC Has $107.95 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

TimesSquare Capital Management LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 201,276 shares of the company’s stock after acquiring an additional 3,530 shares during the period. IDEXX Laboratories accounts for about 1.6% of TimesSquare Capital Management LLC’s holdings, making the stock its 12th biggest position. TimesSquare Capital Management LLC owned approximately 0.25% of IDEXX Laboratories worth $107,952,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Vanguard Group Inc. grew its position in IDEXX Laboratories by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock valued at $4,139,001,000 after purchasing an additional 146,427 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after buying an additional 825,965 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 156.2% in the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after buying an additional 884,808 shares in the last quarter. Invesco Ltd. grew its holdings in shares of IDEXX Laboratories by 0.5% during the first quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock valued at $489,832,000 after buying an additional 5,418 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of IDEXX Laboratories by 37.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock worth $452,046,000 after acquiring an additional 290,551 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $712.47 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The firm has a market cap of $56.89 billion, a price-to-earnings ratio of 59.32, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The firm’s 50-day simple moving average is $647.99 and its two-hundred day simple moving average is $584.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.26. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on IDXX. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. Finally, BTIG Research boosted their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $730.50.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The SEC filing for this sale provides additional information. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.